NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar AntibodiesRead the full report: https://www.reportlinker.com/p04974737
The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In 2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 217-page report you will receive 141 charts– all unavailable elsewhere.The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today you stay better informed and ready to act.Report Scope- Global Next-Generation Antibody Therapies Market from 2018-2028Forecast of the Global Next-Generation Antibody Therapies market by Submarket:- Antibody Fragments & ALPs- Antibody-Drug Conjugates- Biosimilar Antibodies- Bispecific Antibodies- Engineered AntibodiesForecast of the Global Antibody Fragments & ALPs submarket by Product:- Kalbitor- Other Antibody FragmentsForecast of the Global Antibody-Drug Conjugates submarket by Product:- Adcetris- Kadcyla- Mylotarg- Other ADCsForecast of the Global Biosimilar Antibodies submarket by Product:- Infliximab- Adalimumab- Rituximab- Bevacizumab- Trastuzumab- Other Biosimilar mAbsForecast of the Global Bispecific Antibodies submarket by Product:- Blincyto- Hemlibra- Other Bispecific AntibodiesForecast of the Global Engineered Antibodies submarket by Product:- Gazyva/Gazyvaro- Poteligeo- Fasenra- Other Engineered AntibodiesThis report provides individual revenue forecasts to 2028 for these regional and national markets:- North America: US, Canada, and Mexico- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe- Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific- LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEAOur study discusses the selected leading companies that are the major players in the next-generation antibody therapies market:- Amgen, Inc.- GlaxoSmithKline (GSK)- Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)- Merck KGaA- Novartis AG- Pfizer, Inc.- Roche- Sanofi- Seattle Genetics, Inc.- Shire plc- This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.- This report also discusses selected at that are in the pipeline.Read the full report: https://www.reportlinker.com/p04974737
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/the-global-acute-myeloid-leukaemia-market-reached-1bn-in-2017-and-is-estimated-to-reach-2-8bn-by-2022--300742362.html
SOURCE Reportlinker